

About the Author

Dr. Fournier Le Ray recently successfully defended a PhD thesis in microbiology. Her research was focused on the in vivo emergence of bedaquiline resistance.

References

1. Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. *Int J Tuberc Lung Dis*. 2018;22:239–45. <https://doi.org/10.5588/ijtld.17.0660>
2. World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020 [cited 2021 Feb 5]. <https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis>
3. Andres S, Merker M, Heyckendorf J, Kalsdorf B, Rumetshofer R, Indra A, et al. Bedaquiline-resistant tuberculosis: dark clouds on the horizon. *Am J Respir Crit Care Med*. 2020;201:1564–8. <https://doi.org/10.1164/rccm.201909-1819LE>
4. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, et al. Acquired resistance of *Mycobacterium tuberculosis* to bedaquiline. *PLoS One*. 2014;9:e102135. <https://doi.org/10.1371/journal.pone.0102135>
5. Peretokina IV, Krylova LY, Antonova OV, Kholina MS, Kulagina EV, Nosova EY, et al. Reduced susceptibility and resistance to bedaquiline in clinical *M. tuberculosis* isolates. *J Infect*. 2020;80:527–35. <https://doi.org/10.1016/j.jinf.2020.01.007>
6. World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. 2018 [cited 2018 Oct 18]. <https://apps.who.int/iris/handle/10665/275469>
7. Battaglia S, Spitaleri A, Cabibbe AM, Meehan CJ, Utpatel C, Ismail N, et al. Characterization of genomic variants associated with resistance to bedaquiline and delamanid in naive mycobacterium tuberculosis clinical strains. *J Clin Microbiol*. 2020;58:1304–24. <https://doi.org/10.1128/JCM.01304-20>
8. Ismail N, Ismail NA, Omar SV, Peters RPH. In vitro study of stepwise acquisition of rv0678 and atpE mutations conferring bedaquiline resistance. *Antimicrob Agents Chemother*. 2019;63:e00292–19. <https://doi.org/10.1128/AAC.00292-19>
9. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in *Mycobacterium tuberculosis* to a novel diarylquinoline ATP synthase inhibitor. *Antimicrob Agents Chemother*. 2010;54:1022–8. <https://doi.org/10.1128/AAC.01611-09>
10. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et al. *Mycobacterium tuberculosis* growth at the cavity surface: a microenvironment with failed immunity. *Infect Immun*. 2003;71:7099–108. <https://doi.org/10.1128/IAI.71.12.7099-7108.2003>
11. World Health Organization. Catalogue of mutations in *Mycobacterium tuberculosis* complex and their association with drug resistance [cited 2022 Jan 18]. <https://www.who.int/publications-detail-redirect/9789240028173>

Address for correspondence: Nicolas Veziris, Faculté de Médecine Sorbonne Université, 91, boulevard de l'hôpital, 75013 Paris, France; email: nicolas.veziris@sorbonne-universite.fr

Emerging Novel Reassortant Influenza A(H5N6) Viruses in Poultry and Humans, China, 2021

Wenming Jiang, Chunxia Dong, Shuo Liu, Cheng Peng, Xin Yin, Shaobo Liang, Lin Zhang, Jinping Li, Xiaohui Yu, Yang Li, Jingjing Wang, Guangyu Hou, Zheng Zeng, Hualei Liu

Author affiliations: China Animal Health and Epidemiology Center, Qingdao, China (W. Jiang, S. Liu, C. Peng, X. Yin, S. Liang, L. Zhang, J. Li, X. Yu, Y. Li, J. Wang, G. Hou, H. Liu); Chongqing Animal Disease Prevention and Control Center, Chongqing, China (C. Dong, Z. Zeng)

DOI: <https://doi.org/10.3201/eid2805.212163>

A novel highly pathogenic avian influenza A(H5N6) clade 2.3.4.4b virus was isolated from a poultry market in China that a person with a confirmed case had visited. Most genes of the avian and human H5N6 isolates were closely related. The virus also exhibited distinct antigenicity to the Re-11 vaccine strain.

Highly pathogenic avian influenza A(H5N1) virus emerged in China in 1996. H5 viruses have spread to Eurasia since 2003, Africa since 2005, and North America since 2014–2015. These viruses cause huge economic losses to the poultry industry and pose substantial threats to human health. By March 2022, a total of 75 confirmed cases of human infection with influenza A(H5N6) virus had been reported, including 48 cases in China since 2021 (<https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary>).

On July 9, 2021, a human case of H5N6 infection was reported in Chongqing, China. One day later, we conducted an epidemiologic survey in the poultry market the patient had visited and collected swab samples from poultry. We identified the samples as H5N6 subtype by using H5- and N6-specific primers and probes. We propagated the virus in 10-day-old specific pathogen-free chicken embryos and designated the isolate as A/chicken/Chongqing/H1/2021(H5N6) (CK/CQ/H1). We sequenced the viral genome by using the Sanger method and deposited the sequences in GISAID (<https://www.gisaid.org>; accession nos. EPI1937512–9).

Phylogenetic analysis of the hemagglutinin (HA) genes showed that CK/CQ/H1 and A/Chongqing/

02/2021 were closely related genetically and belonged to subclade 2.3.4.4b, along with H5N6 human isolates from Sichuan (2021) and Hunan (2021) Provinces, indicating that their HA genes likely derived from wild bird strains that arrived in China in 2020 (Figure). Phylogenetic analysis of the neuraminidase (NA) genes showed that the isolate were most closely related to H5N6 isolates (subclade 2.3.4.4h) from China (Figure). The H5N8 viruses that arrived in China in late 2020 appear to have reassorted with clade 2.3.4.4h H5N6 viruses already circulating.

Sequence analysis suggested that the polymerase basic protein 1, polymerase acidic protein, and nucleoprotein genes of CK/CQ/H1 were closely related to those of H5N6 viruses in China, such as A/Environment/Guangdong/C18277136/2018(H5N6) and A/Muscovy duck/China/FJFZ21/2020(H5N6). The matrix protein gene was most closely related to those of H5N8 viruses in Korea and China such as A/wild bird/Korea/H496-3/2020(H5N8) and A/Cygnus columbianus/Hubei/49/2020(H5N8), the polymerase basic protein 2 gene to those of A/Environment/Guangxi/28753/2014(H3N2), and the non-

structural protein gene to those of A/Environment/Jiangxi/47054/2016(H4N2) (Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/28/5/21-2163-App1.pdf>). These findings indicate that CK/CQ/H1 is a new reassortant virus with genes derived from different avian influenza virus subtypes in eastern Asia.

Analysis based on the HA amino acid sequence revealed the presence of a cleavage site (PLREKRRKR/GLF), suggesting that the isolate was highly pathogenic in chickens. The presence of receptor binding sites Q226 and G228 (H3 numbering) indicate that the isolate would preferentially bind to avian-like receptors (1). However, the receptor binding site mutations A137, N158, A160, N186, I192, Q222, and R227 (H3 numbering) could increase binding to human-like receptors (2-5).

Bioinformatics analysis identified many mutations that would increase virulence in mice, such as R114 and I115 (H3 numbering) of the HA gene; D30, M43, and A215 of the matrix protein 1 gene; S42, E55E, E66, M106, and F138 of the nonstructural protein 1 gene; the nonstructural protein 1 C-terminal ESEV motif of the PDZ domain at position aa 227-230; V89, D309, K339, G477, V495, E627, and T676 of




Figure. Phylogenetic trees of hemagglutinin (A) and neuraminidase (B) genes of H5 and N6 subtype influenza viruses collected from poultry and humans in China, 2021, and reference viruses. Red triangles indicate virus obtained in this study; red circles indicate human-infected avian influenza viruses; green squares indicate H5 Re-11 vaccine strain. Clade numbers and lineages are indicated on the right in panel. Trees were constructed with MEGA 5.10 software (<https://www.megasoftware.net>) using the neighbor-joining method. Bootstrap analysis was performed with 1,000 replications. Scale bars indicate nucleotide substitutions per site.

the polymerase basic protein 2 gene; V3 and G622 of the polymerase basic protein 1 gene; and D383 of the polymerase acidic protein gene (6). Mice inoculated with CK/CQ/H1 experienced a rapid and dramatic weight loss of >30%, had signs of illness, and died within 8 days (Appendix Figure).

Since 2019, the inactivated reassortant vaccine H5 Re-11 (clade 2.3.4.4h) has been used in China to control clade 2.3.4.4 viruses. We analyzed differences in antigenicity between CK/CQ/H1 and Re-11. The hemagglutination inhibition titer of Re-11 antiserum against CK/CQ/H1 was 5 log₂ lower than that against the homologous Re-11 antigen, indicating that CK/CQ/H1 exhibited greater antigenic drift relative to the Re-11 vaccine strain. The variations of antigenicity-associated amino acid sites on HA might indicate the potential antigenic drift of CK/CQ/H1 (7) (Appendix Table 2).

We also evaluated the protective efficiency of Re-11 vaccine against the isolate. We vaccinated 3-week-old specific pathogen-free chickens with the Re-11 vaccine. At 21 days after vaccination, the vaccine induced very high levels of antibody against the vaccine antigen. Then, the birds were intranasally challenged with 10⁶ 50% egg infectious dose of CK/CQ/H1. All vaccinated birds displayed no clinical signs and survived, but 2 of them shed virus (Appendix Table 3). The results were inconsistent with those of Cui et al. (8), which may be related to bird species and immune background.

Novel H5N8 viruses of clade 2.3.4.4b virus have spread to China through migratory birds in late 2020 (9,10). These viruses are similar to those that were dominant in Europe from the autumn of 2020 through 2021 but have undergone reassortment since arriving in China, producing novel viruses like CK/CQ/H1. The novel virus we identified is highly pathogenic to both chickens and mice and exhibited distinct antigenicity to the Re-11 vaccine strain, which could not provide complete protection. Under field conditions, birds are unlikely to get sustained high levels of antibody and would more likely be susceptible to infection and virus shedding. New antigen-matched vaccines and more productive measures are needed to prevent and control novel H5N6 infection in poultry and humans.

This work was supported by the National Key Research and Development Program (grant no. 2021YFD1800201).

About the Author

Dr. Jiang is a veterinary researcher at the China Animal Health and Epidemiology Center. His research interests are the epidemiology and control of avian influenza virus.

References

1. Tharakaraman K, Raman R, Viswanathan K, Stebbins NW, Jayaraman A, Krishnan A, et al. Structural determinants for naturally evolving H5N1 hemagglutinin to switch its receptor specificity. *Cell*. 2013;153:1475–85. <https://doi.org/10.1016/j.cell.2013.05.035>
2. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, Smith DF, et al. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. *Science*. 2007;317:825–8. <https://doi.org/10.1126/science.1135165>
3. Wang W, Lu B, Zhou H, Suguitan AL Jr, Cheng X, Subbarao K, et al. Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. *J Virol*. 2010;84:6570–7. <https://doi.org/10.1128/JVI.00221-10>
4. Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, Li Z, et al. Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. *PLoS Pathog*. 2009;5:e1000709. <https://doi.org/10.1371/journal.ppat.1000709>
5. Guo H, de Vries E, McBride R, Dekkers J, Peng W, Bouwman KM, et al. Highly pathogenic influenza A(H5Nx) viruses with altered H5 receptor-binding specificity. *Emerg Infect Dis*. 2017;23:220–31. <https://doi.org/10.3201/eid2302.161072>
6. Suttie A, Deng YM, Greenhill AR, Dussart P, Horwood PF, Karlsson EA. Inventory of molecular markers affecting biological characteristics of avian influenza A viruses. *Virus Genes*. 2019;55:739–68. <https://doi.org/10.1007/s11262-019-01700-z>
7. Li J, Zhang C, Cao J, Yang Y, Dong H, Cui Y, et al. Re-emergence of H5N8 highly pathogenic avian influenza virus in wild birds, China. *Emerg Microbes Infect*. 2021;10:1819–23. <https://doi.org/10.1080/22221751.2021.1968317>
8. Cui P, Zeng X, Li X, Li Y, Shi J, Zhao C, et al. Genetic and biological characteristics of the globally circulating H5N8 avian influenza viruses and the protective efficacy offered by the poultry vaccine currently used in China. *Sci China Life Sci*. 2021. <https://doi.org/10.1007/s11427-021-2025-y>
9. Li X, Lv X, Li Y, Peng P, Zhou R, Qin S, et al. Highly pathogenic avian influenza A(H5N8) virus in swans, China, 2020. *Emerg Infect Dis*. 2021;27:1732–4. <https://doi.org/10.3201/eid2706.204727>
10. He G, Ming L, Li X, Song Y, Tang L, Ma M, et al. Genetically divergent highly pathogenic avian influenza A(H5N8) viruses in wild birds, eastern China. *Emerg Infect Dis*. 2021;27:2940–3. <https://doi.org/10.3201/eid2711.204893>

Address for correspondence: Hualei Liu, Avian Diseases Surveillance Laboratory, China Animal Health and Epidemiology Center, No. 369 Nanjing Rd, Qingdao, 266032, China; email: liuhualei@cahec.cn

Emerging Novel Reassortant Influenza A(H5N6) Viruses in Poultry and Humans, China, 2021

Appendix

Appendix Table 1. Percentage homology of influenza viruses closely related to A/chicken/Chongqing/H1/2021(H5N6).

Segment	Virus	Nucleotide homology (%)
PB2	A/Sichuan/06681/2021(H5N6)	99.4
	A/Environment/Guangxi/28753/2014(H3N2)	97.3
PB1	A/Sichuan/06681/2021(A/H5N6)	98.5
	A/Environment/Guangdong/C18277136/2018(H5N6)	97.8
PA	A/Sichuan/06681/2021(A/H5N6)	99.7
	A/Environment/Guangdong/C17277346/2017(H5N6)	97.6
HA	A/Chongqing/02/2021(H5N6)	99.9
	A/Sichuan/06689/2021(H5N6)	99.8
	A/chicken/Korea/H544/2020(H5N8)	99.6
	A/duck/Korea/H538/2020(H5N8)	99.6
	A/duck/Korea/H499/2020(H5N8)	99.6
NP	A/Sichuan/06681/2021(H5N6)	99.6
	A/Anhui/2021-00011/2020(H5N6)	99.3
	A/Muscovy duck/China/FJFZ21/2020(H5N6)	99.3
NA	A/Chongqing/02/2021(H5N6)	97.5
	A/Sichuan/06689/2021(H5N6)	97.5
	A/Sichuan/06681/2021(H5N6)	97.4
	A/Anhui/2021-00011/2020(H5N6)	97.1
	A/Chongqing/00013/2021(H5N6)	97.0
	A/Muscovy duck/China/FJFZ21/2020(H5N6)	96.6
M	A/Cygnus columbianus/Hubei/49/2020(H5N8)	99.8
	A/wild bird/Korea/H496-3/2020(H5N8)	99.8
	A/chicken/Kostroma/304-10/2020 (H5N8)	99.8
	A/mallard/Kagoshima/KU-d89/2021 (H5N8)	99.8
	A/duck/Northern China/LSP/2020(H5N8)	99.8
	A/turkey/Omsk/0003/2020(H5N8)	99.8

Segment	Virus	Nucleotide homology (%)
NS	A/Sichuan/06681/2021(H5N6)	99.6
	A/Environment/Jiangxi/47054/2016(H4N2)	98.0
	A/Environment/Hunan/34019/2017(H3N2)	97.9

Appendix Table 2. The differences in antigenicity sites on HA between A/chicken/Chongqing/H1/2021(H5N6) and Re-11 vaccine strain


Strains	site A				site B				site C				site D				site E				Other antigenicity associated sites in HA1 (except regions A, B, C, D, E)							
	H3 numbering	130	133	144	145	128	155	187	192	276	173	227	238	240	260	262	93	101	119	120	125	166	202	271	272	285		
Re-11	/	S	V	A	S	T	S	T	N	K	H	R	N	I	T	S	N	T	Q	R	M	V	E	I	I			
CK/CQ/H1	E	L	A	P	P	I	N	I	H	R	R	K	D	V	K	A	S	I	L	S	I	I	G	V	V			

Appendix Table 3. Protection efficacy of H5 Re-11 vaccine against A/chicken/Chongqing/H1/2021(H5N6) in chickens*

Group	Vaccine	Challenge test results, by swab type, no. positive birds/no.tested (mean titer±SD)†						No.surviving birds/total no.
		HI titer±SD, log2		3 dpi		5 dpi		
		Re-11	Isolate	Tracheal	Cloacal	Tracheal	Cloacal	
CK/CQ/H1	Re-11	9.3 ± 0.38	4.2 ± 0.32	2/10 (3.67 ± 1.18)	2/10 (3.81 ± 1.32)	2/10 (3.79 ± 1.26)	2/10 (3.92 ± 1.42)	10/10
Mock		ND	ND	4/4 (4.10 ± 1.23)	4/4 (4.63 ± 1.76)	ND	ND	0/10

*Chickens were immunized with the Re-11 vaccine, and HI antibody titers were determined on day 21 post-vaccination. HI, hemagglutination inhibition assay; dpi, days post-infection; ND, not done.

†Chickens were challenged with 10⁶ 50% egg infectious dose (EID₅₀) of A/chicken/Chongqing/H1/2021(H5N6) virus; virus titers are expressed as log₁₀ EID₅₀/0.1 ml.



Appendix Figure. Virulence of the novel H5N6 virus in Balb/c mice intranasally inoculated with a 10^6 EID₅₀ virus. Bodyweight changes (A) and mortality (B) of BALB/c mice were monitored daily for 14 days.